Chronic kidney disease (CKD) prevalence among U.S. adults has remained steady at approximately 14.8% over the past decade, despite the introduction of new kidney-protective therapies. According to data from the National Health and Nutrition Examination Survey (NHANES) analyzed by researchers at the Boston University Chobanian & Avedisian School of Medicine, an estimated 36 million Americans are currently living with the condition. While overall rates have plateaued, the prevalence of diabetes-related CKD increased from 4.7% to 5.7% between the 2013-2014 and 2021-2023 survey cycles.
Why are CKD rates stagnant despite medical advancements?
New drug classes, including SGLT2 inhibitors and the nonsteroidal mineralocorticoid receptor antagonist finerenone (Kerendia), were designed to protect kidney function. However, Ashish Verma, MBBS, and Sophie Claudel, MD, noted in the New England Journal of Medicine that these advancements have not yet translated into lower population-level prevalence. The researchers attribute this to “stagnant and suboptimal” blood pressure and glycemic control throughout the decade-long study period.
The Centers for Disease Control and Prevention (CDC) estimates that roughly 87% of adults living with chronic kidney disease are completely unaware they have the condition, highlighting a massive gap in early detection.
How does diabetes impact kidney health trends?
Diabetes remains the strongest driver of CKD, with an adjusted prevalence ratio of 2.49. According to the study, the link between diabetes and kidney disease is strengthening rather than weakening. Claudel emphasized that “kidney disease no longer travels alone,” noting that one in four Americans with heart disease also suffers from CKD. This pattern suggests a rise in cardiovascular-kidney-metabolic (CKM) syndrome, where these conditions exacerbate one another in the same patient.
What are the primary risk factors for CKD?
The analysis of 25,106 adults revealed that CKD prevalence is not uniform across the population. Researchers observed higher rates among Black adults and individuals living below the federal poverty threshold. Socioeconomic status and education levels also correlated with higher disease burdens. Throughout the study, more participants met the criteria for CKD based on albuminuria—protein in the urine—than those identified by low estimated glomerular filtration rate (eGFR) alone (8.6% versus 4.1%).
Pro Tip: The Importance of Screening
Experts suggest that routine albuminuria testing for high-risk groups—specifically those with hypertension, diabetes, or existing cardiovascular disease—could be a key intervention. Early detection through these screenings, combined with equitable access to protective medications, is viewed as a path to shifting current prevalence trends.
What is the economic and global burden of the disease?
The financial and human cost of CKD is substantial. In the United States, the condition accounts for $141 billion in annual Medicare fee-for-service spending. Globally, the situation is increasingly dire; as of 2023, CKD reached the top 10 list of leading causes of death worldwide, resulting in 1.48 million deaths. It is currently ranked as the 12th leading cause of lost disability-adjusted life-years.
Frequently Asked Questions
- What defines chronic kidney disease in clinical data? Researchers define CKD as an eGFR of less than 60 mL/min/1.73 m² or a urinary albumin-to-creatinine ratio of 30 mg/g or higher.
- Are heart failure and kidney disease related? Yes. Heart failure is strongly linked to CKD, with data showing an adjusted prevalence ratio of 2.47, making it nearly as significant a co-morbidity as diabetes.
- Why is CKD awareness so low? The CDC reports that roughly 87% of adults with CKD were unaware they had it.
Are you interested in learning more about managing chronic conditions? Subscribe to our health newsletter for the latest updates on medical research and patient advocacy.
